Global Immune Checkpoint Blockers 麻豆原创 Growth 2025-2031

Publication ID:

LPI08255445

Publication Date:

August 7, 2025

Pages:

101

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Immune Checkpoint Blockers market size is predicted to grow from US$ 27500 million in 2025 to US$ 72800 million in 2031; it is expected to grow at a CAGR of 17.6% from 2025 to 2031.
Immune Checkpoint Blockers are a class of drugs that enhance the immune system's ability to target tumors by inhibiting the action of negative regulatory molecules within the immune system. Immune checkpoints are molecules on the surface of immune cells that normally limit immune responses to prevent damage to the body's own tissues. However, tumor cells often exploit these checkpoints to evade immune surveillance, thus promoting tumor growth and spread.
Immune checkpoint blockers work by blocking these checkpoint receptors (such as PD-1, CTLA-4, etc.), removing the suppression on the immune system and restoring immune cells' anti-tumor functions. The most common immune checkpoint blockers include anti-PD-1 antibodies (such as nivolumab, pembrolizumab) and anti-CTLA-4 antibodies (such as ipilimumab). These drugs have shown significant effectiveness in treating various cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma.
Immune checkpoint blockers provide new treatment options for patients with advanced cancers, especially when traditional treatments are ineffective, significantly improving patient survival rates. They represent a major advancement in immunotherapy, changing the landscape of cancer treatment and offering new hope for the future of cancer therapy.
麻豆原创 Development Opportunities and Key Drivers
The immune checkpoint blockers market is growing rapidly, driven by several key factors. First, there is an increasing demand for new treatment options as traditional therapies become less effective, especially for advanced cancers. Immune checkpoint blockers have shown significant efficacy across various cancer types, leading to expanding market demand. Second, ongoing innovation in drug development is introducing more immune checkpoint blockers into clinical use, providing more treatment options. Additionally, the rising global cancer incidence and aging population are further driving market growth.
麻豆原创 Risks
The immune checkpoint blockers market also faces several challenges. First, the high cost of treatment may limit access in certain regions or among specific populations. Second, some patients may experience immune-related side effects or develop resistance to the therapy, which can affect treatment efficacy and continuity. Moreover, as more competitors enter the market, including the emergence of new immunotherapies, competition may intensify, requiring companies to maintain an edge in innovation and efficacy.
Downstream Demand Trends
In the future, demand for immune checkpoint blockers will be driven by the rise of personalized treatment and combination therapy models. Personalized treatment can tailor therapy based on a patient's genetic and tumor characteristics, improving treatment outcomes. Additionally, the trend of combining immune checkpoint blockers with other therapies (such as chemotherapy and targeted drugs) is increasing, creating new growth opportunities in the market. With advancements in early cancer diagnosis technology, the application of immune checkpoint blockers may expand to early-stage cancer treatments as well.
The 鈥淚mmune Checkpoint Blockers Industry Forecast鈥� looks at past sales and reviews total world Immune Checkpoint Blockers sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Blockers sales for 2025 through 2031. With Immune Checkpoint Blockers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune Checkpoint Blockers industry.
This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Blockers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Blockers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Immune Checkpoint Blockers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Blockers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Blockers.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Blockers market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Anti-PD-L1 Drug
Anti-PD-1 Drug
CTLA4
Segmentation by Application:
Lung Cancer
Colorectal Cancer
BreastCancer
Prostate Cancer
Melanoma
Blood Cancers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
AbbVie
Bristol Myers Squibb
Merck
AstraZeneca
Roche
Key Questions Addressed in this Report
What is the 10-year outlook for the global Immune Checkpoint Blockers market?
What factors are driving Immune Checkpoint Blockers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immune Checkpoint Blockers market opportunities vary by end market size?
How does Immune Checkpoint Blockers break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Immune Checkpoint Blockers Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Immune Checkpoint Blockers by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Immune Checkpoint Blockers by Country/Region, 2020, 2024 & 2031
2.2 Immune Checkpoint Blockers Segment by Type
2.2.1 Anti-PD-L1 Drug
2.2.2 Anti-PD-1 Drug
2.2.3 CTLA4
2.3 Immune Checkpoint Blockers Sales by Type
2.3.1 Global Immune Checkpoint Blockers Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Immune Checkpoint Blockers Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Immune Checkpoint Blockers Sale Price by Type (2020-2025)
2.4 Immune Checkpoint Blockers Segment by Application
2.4.1 Lung Cancer
2.4.2 Colorectal Cancer
2.4.3 BreastCancer
2.4.4 Prostate Cancer
2.4.5 Melanoma
2.4.6 Blood Cancers
2.5 Immune Checkpoint Blockers Sales by Application
2.5.1 Global Immune Checkpoint Blockers Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Immune Checkpoint Blockers Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Immune Checkpoint Blockers Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Immune Checkpoint Blockers Breakdown Data by Company
3.1.1 Global Immune Checkpoint Blockers Annual Sales by Company (2020-2025)
3.1.2 Global Immune Checkpoint Blockers Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Immune Checkpoint Blockers Annual Revenue by Company (2020-2025)
3.2.1 Global Immune Checkpoint Blockers Revenue by Company (2020-2025)
3.2.2 Global Immune Checkpoint Blockers Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Immune Checkpoint Blockers Sale Price by Company
3.4 Key Manufacturers Immune Checkpoint Blockers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Checkpoint Blockers Product Location Distribution
3.4.2 Players Immune Checkpoint Blockers Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Immune Checkpoint Blockers by Geographic Region
4.1 World Historic Immune Checkpoint Blockers 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Immune Checkpoint Blockers Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Immune Checkpoint Blockers Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Immune Checkpoint Blockers 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Immune Checkpoint Blockers Annual Sales by Country/Region (2020-2025)
4.2.2 Global Immune Checkpoint Blockers Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immune Checkpoint Blockers Sales Growth
4.4 APAC Immune Checkpoint Blockers Sales Growth
4.5 Europe Immune Checkpoint Blockers Sales Growth
4.6 Middle East & Africa Immune Checkpoint Blockers Sales Growth
5 Americas
5.1 Americas Immune Checkpoint Blockers Sales by Country
5.1.1 Americas Immune Checkpoint Blockers Sales by Country (2020-2025)
5.1.2 Americas Immune Checkpoint Blockers Revenue by Country (2020-2025)
5.2 Americas Immune Checkpoint Blockers Sales by Type (2020-2025)
5.3 Americas Immune Checkpoint Blockers Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Checkpoint Blockers Sales by Region
6.1.1 APAC Immune Checkpoint Blockers Sales by Region (2020-2025)
6.1.2 APAC Immune Checkpoint Blockers Revenue by Region (2020-2025)
6.2 APAC Immune Checkpoint Blockers Sales by Type (2020-2025)
6.3 APAC Immune Checkpoint Blockers Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Immune Checkpoint Blockers by Country
7.1.1 Europe Immune Checkpoint Blockers Sales by Country (2020-2025)
7.1.2 Europe Immune Checkpoint Blockers Revenue by Country (2020-2025)
7.2 Europe Immune Checkpoint Blockers Sales by Type (2020-2025)
7.3 Europe Immune Checkpoint Blockers Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immune Checkpoint Blockers by Country
8.1.1 Middle East & Africa Immune Checkpoint Blockers Sales by Country (2020-2025)
8.1.2 Middle East & Africa Immune Checkpoint Blockers Revenue by Country (2020-2025)
8.2 Middle East & Africa Immune Checkpoint Blockers Sales by Type (2020-2025)
8.3 Middle East & Africa Immune Checkpoint Blockers Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Blockers
10.3 Manufacturing Process Analysis of Immune Checkpoint Blockers
10.4 Industry Chain Structure of Immune Checkpoint Blockers
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Checkpoint Blockers Distributors
11.3 Immune Checkpoint Blockers Customer
12 World Forecast Review for Immune Checkpoint Blockers by Geographic Region
12.1 Global Immune Checkpoint Blockers 麻豆原创 Size Forecast by Region
12.1.1 Global Immune Checkpoint Blockers Forecast by Region (2026-2031)
12.1.2 Global Immune Checkpoint Blockers Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Immune Checkpoint Blockers Forecast by Type (2026-2031)
12.7 Global Immune Checkpoint Blockers Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Immune Checkpoint Blockers Product Portfolios and Specifications
13.1.3 Sanofi Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 AbbVie
13.2.1 AbbVie Company Information
13.2.2 AbbVie Immune Checkpoint Blockers Product Portfolios and Specifications
13.2.3 AbbVie Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AbbVie Main Business Overview
13.2.5 AbbVie Latest Developments
13.3 Bristol Myers Squibb
13.3.1 Bristol Myers Squibb Company Information
13.3.2 Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolios and Specifications
13.3.3 Bristol Myers Squibb Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bristol Myers Squibb Main Business Overview
13.3.5 Bristol Myers Squibb Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck Immune Checkpoint Blockers Product Portfolios and Specifications
13.4.3 Merck Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Immune Checkpoint Blockers Product Portfolios and Specifications
13.5.3 AstraZeneca Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Roche
13.6.1 Roche Company Information
13.6.2 Roche Immune Checkpoint Blockers Product Portfolios and Specifications
13.6.3 Roche Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Roche Main Business Overview
13.6.5 Roche Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.